Achiko AG Appoints Toolbox Medical Innovations and NDA Group and Expands Advisory Board
11/02/2020 | 08:52am EST
Encouraging Initial Results to Date in Field Validation Trials
Toolbox Medical Innovations Engaged for the Design of the Commercial Test Kit
NDA Group Engaged to Assist in Progress Towards CE Marking
Additional International Advisory Board Members: Paul Field (Australia) and Charles Pan (Taiwan)
ZURICH, Switzerland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Achiko AG (SWX: ACHI, ISIN CH0522213468) has engaged Toolbox Medical innovations and NDA Group in its expanding global strategy to bring the Gumnuts protocol for saliva based Covid-19 tests into commercial availability.
“We are encouraged with the field studies so far, and expanding our global ambitions,” said Steven Goh, CEO. “Toolbox and NDA Group along with our go forward executive team and advisory board will be important for the group in bringing Gumnuts to the market in the ensuing months.”
Toolbox Medical Innovations will assist with the design of the commercial version of the test kit. Toolbox is an ISO 13485-certified consumables development firm and a full contract research organization (CRO) which develops and manufactures life science and diagnostic products with a focus on in vitro diagnostics (IVD).
Achiko has engaged NDA Group to assist with implementing and improving the Company’s Quality Management System and progress towards CE marking. NDA Group is a world leading regulatory and drug development consultancy with a dedicated team of over 150 consultants supported by an expert network and a specialist Advisory Board.
Furthermore, to support the company, we are proud to announce an expansion of the Company’s advisory board:
Mr. Paul Field was previously with Austrade and has over 30 years of international biotech and, in particular, diagnostics experience. Currently with the Horizon 3 Biotech Fund, Strategic Advisor to Alsonex, Marinova and other Australian biotech companies, Paul is the Australian representative for the Geneva-based Global Antibiotic R&D Partnership (GARDP).
Mr. Charles Pan has over 25 years of professional venture and private equity investment experience in East Asia and Silicon Valley, and held positions as Chief Executive Officer at Orange Capital, Special Assistant to the Chairman and Investment Director at Foxconn’s mobile business, and Chief Investment Officer at Eastern Media Group. His experience covers Investment/M&A, strategic partnership, start-up management and ecosystem building with successful investments in multiple unicorn companies. He was recognized in 2016 and 2017 on the “Powerlist 100” investors by Global Corporate Venturing.
ABOUT ACHIKO AG Headquartered in Switzerland, with a global market focus, Achiko AG (SWX:ACHI, ISIN CH0522213468) is an entrepreneurial platform company, utilizing the knowledge and experience of its people and key technologies to enable transformation in various industries.
Through innovations in technology along with the company's unique operating footprint from Europe to Asia, Achiko seeks to transform markets and bring exceptional value to its customers, people, and shareholders. Achiko supports innovations in healthcare through its Teman Sehat ("Health Buddy") ecosystem and a novel saliva based Covid-19 testing technology, codenamed “Gumnuts”, being developed with Regenacellx.sl.
For any inquiries regarding Gumnuts or Teman Sehat, please contact firstname.lastname@example.org
Press Contact Germany and Austria Axel Mühlhaus / Dr Sönke Knop edicto GmbH E: email@example.com T: +49 69 90 55 05-51
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties
and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.